Moxibustion combined with anti-PD-1 antibodies improves immunosuppression in septic mice potentially through the PD-1/PD-L1 pathway.

Authors

Yin Han, Hui Zhang, Jin Han, Shanming Han

Published in

Immunologic research. Volume 74. Issue 1. Jun 17, 2026. Epub Jun 17, 2026.

Abstract

This study was to investigate the therapeutic effects of moxibustion (Mox) combined with anti-PD-1 antibody on septic mice and the immune regulatory mechanism based on the PD-1/PD-L1 axis. A CLP-induced sepsis mouse model was established and intervened with moxibustion and/or anti-PD-1 antibody. It was found that both Mox and anti-PD-1 monotherapy improved mouse survival rates, reduced murine sepsis score, alleviated pathological damage in the liver, lungs, and spleen, mitigated serum biochemical abnormalities, and regulated systemic and local organ inflammation. Combination therapy demonstrated synergistic enhancement effects, yielding the most significant improvements across all metrics. Combination therapy effectively reduced intraperitoneal bacterial load and enhanced macrophage recruitment, reversed sepsis-induced decreases in spleen T cell (CD3⁺, CD4⁺, CD8⁺) proportions and CD3⁺ T cell apoptosis, corrected Th1/Th2 imbalance, and significantly downregulated PD-1 expression on spleen T cells and PD-L1 expression on neutrophils. Combination therapy suppressed PD-1, PD-L1, and STAT3 expression in the spleen while reducing STAT3 nuclear translocation. Combination therapy effectively alleviates early inflammatory storms and late-stage immunosuppression in sepsis, potentially through regulation of the PD-1/PD-L1/STAT3 signaling pathway.

PMID:
42307810
Bibliographic data and abstract were imported from PubMed on 17 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.